PRESS RELEASE published on 01/20/2026 at 18:00, 3 months 17 days ago THX Pharma Announces its 2026 Financial Calendar THX Pharma (Theranexus) announces financial communication agenda for 2026, focusing on rare neurological diseases treatments. Company listed on Euronext Growth Paris Euronext Growth Paris Financial Communication Theranexus Neurological Diseases THX Pharma
PRESS RELEASE published on 01/20/2026 at 18:00, 3 months 17 days ago THX Pharma publie son agenda financier 2026 THX Pharma publie son agenda financier 2026, incluant les dates de communication financière et informations sur ses médicaments innovants. Retrouvez plus d'informations sur http://www.theranexus.com Communication Financière Agenda Financier Médicaments Neurologiques Rares THX Pharma
BRIEF published on 01/08/2026 at 18:05, 3 months 29 days ago Publication of the letter to shareholders by Theranexus Shareholders Neuroscience Rare Diseases Theranexus Drugs
BRIEF published on 01/08/2026 at 18:05, 3 months 29 days ago Publication de la lettre aux actionnaires par Theranexus Actionnaires Médicaments Maladies Rares Theranexus Neurosciences
BRIEF published on 01/08/2026 at 18:05, 3 months 29 days ago THX Pharma Releases Shareholder Letter Drug Development Biopharmaceutical Shareholder Communication Neurological Diseases THX Pharma
BRIEF published on 01/08/2026 at 18:05, 3 months 29 days ago THX Pharma publie une lettre aux actionnaires Biopharmaceutique Communication Aux Actionnaires Développement De Médicaments Maladies Neurologiques THX Pharma
PRESS RELEASE published on 01/08/2026 at 18:00, 3 months 29 days ago THX Pharma annonce la publication de sa lettre aux actionnaires Theranexus annonce la publication de sa lettre aux actionnaires. THX Pharma se spécialise dans le traitement des maladies neurologiques rares. Plus d'infos sur leur site Actionnaires Newsletter Theranexus Maladies Neurologiques Rares THX Pharma
PRESS RELEASE published on 01/08/2026 at 18:00, 3 months 29 days ago THX Pharma announces the publication of its letter to shareholders THX Pharma (Theranexus) announces the publication of its letter to shareholders, highlighting treatments for rare neurological diseases and upcoming drug commercialization. Forward-looking statements included Forward-looking Statements Theranexus Neurological Diseases THX Pharma Drug Commercialization
BRIEF published on 01/07/2026 at 08:05, 3 months 30 days ago THX Pharma nomme Julien Veys au poste de directeur général adjoint Maladies Neurologiques Rares THX Pharma Nomination De Julien Veys Stratégie Theranexus Commercialisation Pharmaceutique
BRIEF published on 01/07/2026 at 08:05, 3 months 30 days ago THX Pharma nomme Julien Veys au poste de Directeur général adjoint Nomination Stratégie Commerciale THX Pharma Julien Veys Médicaments Neurologiques
Published on 05/07/2026 at 02:00, 55 minutes ago Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New York
Published on 05/06/2026 at 23:30, 3 hours 25 minutes ago Stabilis Solutions Announces First Quarter 2026 Results
Published on 05/06/2026 at 23:05, 3 hours 50 minutes ago Zomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in Liquidity
Published on 05/06/2026 at 23:00, 3 hours 55 minutes ago Green Bridge Metals Strengthens Technical and Strategic Team as 2026 Work Programs Advance
Published on 05/06/2026 at 22:10, 4 hours 45 minutes ago Banyan Gold Announces Closing of $46.5 Million Private Placement
Published on 05/07/2026 at 00:47, 2 hours 8 minutes ago Blue Cap AG expands portfolio through the acquisition of Janoschka AG
Published on 05/07/2026 at 00:43, 2 hours 11 minutes ago EQS-Adhoc: Blue Cap AG Acquires Janoschka AG and Adjusts Forecast Due to Transaction
Published on 05/06/2026 at 20:32, 6 hours 23 minutes ago EQS-Adhoc: Kontron AG: ADHOC Kontron AG / Potential Public Takeover Bid by Ennoconn Corporation
Published on 05/06/2026 at 20:22, 6 hours 33 minutes ago EQS-Adhoc: ams-OSRAM AG: ams OSRAM delivers strong Q1 results, enters AI market through a development agreement with a leading AI photonics customer and sees path to positive Free Cash Flow in 2027
Published on 05/06/2026 at 19:18, 7 hours 37 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/06/2026 at 18:00, 8 hours 54 minutes ago Mise à disposition des documents relatifs à l'AG du 4 juin 2026
Published on 05/06/2026 at 18:00, 8 hours 54 minutes ago Access to information in respect of the General Shareholders’ Meeting to be held on June 4, 2026
Published on 05/06/2026 at 18:00, 8 hours 55 minutes ago Information concerning the total number of voting rights and shares in the share capital as of April 30, 2026
Published on 05/06/2026 at 18:00, 8 hours 55 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 30 avril 2026
Published on 05/06/2026 at 17:45, 9 hours 10 minutes ago Information concerning the total number of voting rights and shares 2026 04 30
